Prevention and partial reversion of the lupus phenotype in ABIN1[D485N] mice by an IRAK4 inhibitor

Tsvetana Petrova, Sambit K. Nanda, Cheryl Scudamore, Stephen W. Wright, Vikram R . Rao, Philip Cohen (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

21 Downloads (Pure)

Abstract

We have reported previously that the IRAK4 inhibitor PF06426779 given to ubiquitin-binding-defective ABIN1[D485N] mice at 6 weeks of age prevents the major facets of lupus that develop 10 weeks later. The present study was undertaken to investigate whether PF06426779 could reverse the lupus phenotype when administered to 13-week-old ABIN1[D485N] mice that had already developed symptoms of lupus. Splenomegaly, the number of splenic neutrophils, TFHand Germinal Centre B (GCB) cells, serum levels of immunoglobulins, the extent of kidney, liver and lung pathology, and glomerular IgA and IgM were measured after feeding 13-week-old ABIN1[D485N] and wild-type mice for another 10 weeks with R&M3 diet with and without PF06426779 (4 g/kg). Following drug treatment, spleen size and weight, splenic neutrophil numbers, and serum IgA and glomerular IgA levels of ABIN1[D485N] mice returned to those seen in wild-type mice. The rise in splenic TFH and GCB numbers, the increase in kidney and liver pathology, and the concentrations of serum IgG1, IgG2A and IgE between 13 and 23 weeks were suppressed. There was no reduction in the level of anti-self double-stranded DNA, anti-self nuclear antigens or IgM during the drug treatment. The results demonstrate the therapeutic potential of IRAK4 inhibitors for the treatment of lupus and raise the possibility of monitoring efficacy by measuring decreases in the serum levels of IgA. Our results support the view that there may be a closer connection between lupus and IgA nephropathy than realised previously.

Original languageEnglish
Article numbere000573
Number of pages5
JournalLupus Science & Medicine
Volume8
Issue number1
DOIs
Publication statusPublished - 26 Nov 2021

Keywords

  • Lupus Nephritis
  • Autoantibodies
  • Therapeutics
  • Anti-Inflammatory Agents
  • therapeutics
  • non-steroidal
  • lupus nephritis
  • anti-inflammatory agents
  • autoantibodies

Fingerprint

Dive into the research topics of 'Prevention and partial reversion of the lupus phenotype in ABIN1[D485N] mice by an IRAK4 inhibitor'. Together they form a unique fingerprint.

Cite this